Your browser is no longer supported. Please, upgrade your browser.
Settings
EGRX Eagle Pharmaceuticals, Inc. daily Stock Chart
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E37.20 EPS (ttm)2.12 Insider Own10.50% Shs Outstand14.69M Perf Week2.28%
Market Cap1.16B Forward P/E16.64 EPS next Y4.74 Insider Trans-0.15% Shs Float12.66M Perf Month-0.95%
Income33.20M PEG10.94 EPS next Q1.01 Inst Own- Short Float19.24% Perf Quarter22.29%
Sales215.70M P/S5.37 EPS this Y-29.80% Inst Trans-0.58% Short Ratio9.81 Perf Half Y32.85%
Book/sh12.48 P/B6.32 EPS next Y21.71% ROA11.20% Target Price78.75 Perf Year41.80%
Cash/sh6.82 P/C11.57 EPS next 5Y3.40% ROE16.70% 52W Range48.84 - 85.66 Perf YTD47.70%
Dividend- P/FCF28.90 EPS past 5Y32.50% ROI24.90% 52W High-7.89% Beta1.36
Dividend %- Quick Ratio4.10 Sales past 5Y147.70% Gross Margin74.20% 52W Low61.55% ATR2.96
Employees108 Current Ratio4.20 Sales Q/Q18.40% Oper. Margin17.50% RSI (14)51.11 Volatility4.98% 3.70%
OptionableYes Debt/Eq0.25 EPS Q/Q-38.50% Profit Margin13.80% Rel Volume0.58 Prev Close79.34
ShortableYes LT Debt/Eq0.22 EarningsAug 07 BMO Payout0.00% Avg Volume248.29K Price78.90
Recom2.00 SMA20-1.33% SMA502.76% SMA20026.59% Volume183,779 Change-0.55%
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Jul-06-15Reiterated Piper Jaffray Overweight $75 → $94
Jun-16-15Reiterated Cantor Fitzgerald Buy $65 → $95
Aug-07-18 08:15AM  Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates Zacks
07:09AM  Eagle Pharmaceuticals: 2Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results Business Wire
06:30AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 11:21AM  Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks
Jul-31-18 08:53AM  NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher Zacks
Jul-30-18 09:30AM  Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-25-18 07:00AM  Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018 Business Wire
Jul-09-18 07:00AM  FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection) Business Wire
Jul-03-18 08:30AM  Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA Business Wire
Jun-29-18 07:30AM  Investor Expectations to Drive Momentum within Education Realty Trust, Eagle Pharmaceuticals, Boingo Wireless, United Parcel Service, Marathon Petroleum, and Coherent Discovering Underlying Factors of Influence GlobeNewswire
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:50AM  Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection) Business Wire
May-29-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June Business Wire
May-18-18 07:40AM  Wired News FDA Granted Approval to Eagle Pharmas Bendamustine Hydrochloride RTD Solution in a 500ml Admixture ACCESSWIRE
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 06:50AM  Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture Business Wire
May-13-18 05:46AM  Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:11AM  Eagle Pharmaceuticals: 1Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results Business Wire
May-02-18 05:11AM  New Strong Sell Stocks for May 2nd Zacks
May-01-18 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018 Business Wire
Apr-30-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference Business Wire
Apr-16-18 07:00AM  Eagle Pharmaceuticals Vasopressin ANDA Accepted for Filing by the FDA Business Wire
Mar-27-18 08:30AM  Eagle Pharmaceuticals Announces New Patent for Eagle Biologics Business Wire
Mar-06-18 07:10AM  Blog Exposure - Mylan Plans to Launch Two New HIV Treatments in the US ACCESSWIRE
Mar-01-18 07:42AM  New Strong Sell Stocks for March 1st Zacks
Feb-27-18 10:55AM  Eagle Pharmaceuticals (EGRX) Q4 2017 Earnings Conference Call Transcript Motley Fool -6.30%
Feb-26-18 10:16PM  Edited Transcript of EGRX earnings conference call or presentation 26-Feb-18 1:30pm GMT Thomson Reuters StreetEvents -8.88%
08:10AM  Recent Analysis Shows Valmont Industries, Guidewire Software, Eagle Pharmaceuticals, Bojangles', INVESCO MORTGAGE CAPITAL INC, and Archrock Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:35AM  Eagle Pharmaceuticals posts 4Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results Business Wire
06:00AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018 Business Wire +5.14%
Feb-12-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference Business Wire
Feb-07-18 07:30AM  Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX Business Wire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +8.97%
06:50AM  Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-17 12:04PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:47AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-21-17 07:14AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : December 21, 2017 Capital Cube
Dec-19-17 08:00AM  Research Report Identifies 2U, AK Steel Holding, American Water Works, Urban Edge Properties, Guidewire Software, and Eagle Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Dec-15-17 07:13PM  Cramer's lightning round: Buy Cisco when it goes below $3... CNBC Videos
Dec-07-17 06:50AM  Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant Business Wire
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-20-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-17 09:01PM  Barron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges Barrons.com
08:36PM  Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-10-17 01:10PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : November 10, 2017 Capital Cube
Nov-09-17 07:21AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017 Capital Cube -7.21%
Nov-08-17 10:44AM  Eagle Pharmaceuticals posts 3Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results Business Wire
06:10AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference Business Wire
Oct-30-17 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 Business Wire -6.52%
Oct-27-17 04:44PM  Eagle Pharma gets tentative FDA approval for Lilly's Alimta version Reuters
03:14PM  FDA tentatively approves Eagle Pharma's cancer drug Reuters
03:02PM  Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute Business Wire
Oct-24-17 09:37AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017 Capital Cube
Oct-17-17 07:33AM  Eagle Pharmaceuticals Announces New Patent for RYANODEX Business Wire
Oct-15-17 12:00PM  3 Biotech Values in a Fully Valued Market TheStreet.com
Oct-13-17 10:44AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-11-17 08:23AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017 Capital Cube
Oct-02-17 10:49AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-28-17 04:21PM  Edited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Sep-25-17 08:52AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 Capital Cube
Sep-22-17 07:40AM  Corporate News Blog - Eagle Pharmas Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products ACCESSWIRE
Sep-20-17 06:50AM  Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Business Wire
Sep-19-17 11:08PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017 Capital Cube
07:57PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : September 19, 2017 Capital Cube
Sep-18-17 09:25AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017 Capital Cube
Sep-06-17 06:50AM  Eagle Pharmaceuticals, Inc. to Present at September Investor Conferences Business Wire
Sep-05-17 10:00AM  Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure Business Wire
Aug-22-17 08:01AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-14-17 03:15PM  Eagle Pharmaceuticals, Inc.: Sudden move in price, will it continue? Capital Cube
Aug-11-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +11.12%
Aug-10-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-09-17 10:25PM  Eagle Pharmaceuticals posts 2Q profit Associated Press +5.09%
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results Business Wire
Aug-03-17 08:12PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : August 4, 2017 Capital Cube
Jul-31-17 06:50AM  Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2017 Financial Results on August 9, 2017 Business Wire
Jul-26-17 03:11PM  Mizuho Top Analyst Buzzes Mayday as Eagle Pharmaceuticals Inc (EGRX) Valuation Likely to Collapse SmarterAnalyst -23.80%
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
01:02PM  UPDATE: Eagle Pharma stock plummets 21% on news that heat stroke drug failed to get FDA approval MarketWatch
12:30PM  Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application Business Wire
Jul-25-17 09:19AM  Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke Business Wire
Jul-24-17 03:38PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
Jul-20-17 01:30PM  3 Stocks the Smartest Investors Are Buying Right Now Motley Fool
Jul-14-17 02:10PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
Jul-11-17 09:18AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 11, 2017 Capital Cube
Jul-03-17 08:13AM  Key FDA Events to Watch Out for in Jul 2017 Zacks
Jun-26-17 08:39AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : June 26, 2017 Capital Cube
Jun-25-17 09:42AM  These 3 Stocks Are Up Over 500% in the Last 3 Years Motley Fool
Jun-19-17 03:14PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : June 19, 2017 Capital Cube
Jun-16-17 02:34PM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-08-17 08:56AM  What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX) Zacks
May-31-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June Business Wire
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tarriff ScottCEOJun 28Option Exercise4.04124,804504,2081,549,959Jul 03 05:09 PM
Tarriff ScottCEOMar 30Option Exercise4.04113,104456,9401,483,050Apr 03 05:05 PM
FLAUM SANDER ADirectorMar 06Sale53.942,340126,22011,374Mar 07 04:16 PM
FLAUM SANDER ADirectorMar 05Option Exercise0.902,3402,10613,714Mar 07 04:16 PM
RATOFF STEVEN BDirectorDec 18Option Exercise0.902,3402,10615,664Dec 20 05:54 PM
Meyers Pete A.Chief Financial OfficerAug 16Buy55.4535019,406700Aug 16 08:30 PM